Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Center for Therapeutic Effectiveness Research, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Clin Pharmacol Ther. 2021 Aug;110(2):409-423. doi: 10.1002/cpt.2195. Epub 2021 Mar 14.
Antidepressants are very widely used and associated with traumatic injury, yet little is known about their potential for harmful drug interactions. We aimed to identify potential drug interaction signals by assessing concomitant medications (precipitant drugs) taken with individual antidepressants (object drugs) that were associated with unintentional traumatic injury. We conducted pharmacoepidemiologic screening of 2000-2015 Optum Clinformatics data, identifying drug interaction signals by performing self-controlled case series studies for antidepressant + precipitant pairs and injury. We included persons aged 16-90 years codispensed an antidepressant and ≥ 1 precipitant drug(s), with an injury during antidepressant therapy. We classified antidepressant person-days as either precipitant-exposed or precipitant-unexposed. The outcome was an emergency department or inpatient discharge diagnosis for unintentional traumatic injury. We used conditional Poisson regression to calculate confounder adjusted rate ratios (RRs) and accounted for multiple estimation via semi-Bayes shrinkage. We identified 330,884 new users of antidepressants who experienced an injury. Among such persons, we studied concomitant use of 7,953 antidepressant + precipitant pairs. Two hundred fifty-six (3.2%) pairs were positively associated with injury and deemed potential drug interaction signals; 22 of these signals had adjusted RRs > 2.00. Adjusted RRs ranged from 1.06 (95% confidence interval: 1.00-1.12, P = 0.04) for citalopram + gabapentin to 3.06 (1.42-6.60) for nefazodone + levonorgestrel. Sixty-five (25.4%) signals are currently reported in a seminal drug interaction knowledgebase. We identified numerous new population-based signals of antidepressant drug interactions associated with unintentional traumatic injury. Future studies, intended to test hypotheses, should confirm or refute these potential interactions.
抗抑郁药的应用非常广泛,与创伤性损伤有关,但人们对其潜在的有害药物相互作用知之甚少。我们旨在通过评估与非故意创伤性损伤相关的个体抗抑郁药(目标药物)同时使用的伴随药物(引发药物)来确定潜在的药物相互作用信号。我们对 2000-2015 年 Optum Clinformatics 数据进行了药物流行病学筛查,通过对抗抑郁药+引发药物对与损伤的自我对照病例系列研究来识别药物相互作用信号。我们纳入了年龄在 16-90 岁之间的患者,这些患者同时服用抗抑郁药和≥1 种引发药物,并在抗抑郁药治疗期间发生了损伤。我们将抗抑郁药的人天分为引发暴露或未暴露。结局是急诊或住院外伤性损伤的诊断。我们使用条件泊松回归计算混杂因素调整后的率比(RR),并通过半贝叶斯收缩法进行多次估计。我们确定了 330884 名新使用抗抑郁药的患者发生了损伤。在这些患者中,我们研究了 7953 对同时使用的抗抑郁药+引发药物对。256 对(3.2%)与损伤呈正相关,被认为是潜在的药物相互作用信号;其中 22 对的调整 RR >2.00。调整后的 RR 范围从西酞普兰+加巴喷丁的 1.06(95%置信区间:1.00-1.12,P=0.04)到奈法唑酮+左炔诺孕酮的 3.06(1.42-6.60)。65 个(25.4%)信号目前在一个主要的药物相互作用知识库中报告。我们确定了许多与非故意创伤性损伤相关的新的基于人群的抗抑郁药药物相互作用信号。未来的研究,旨在验证假设,应该确认或反驳这些潜在的相互作用。